Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Hos Loftus

Psychiatry Shelby, NC Medical Doctor

NPI 1295719920 CMS profile 1169216

202 E Grover St, Ste 1, Shelby, NC 28150

Open in the dashboard

General payments

$1,487

75 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Hos Loftus of Shelby, NC is reported in the CMS Open Payments database as having received $1,487 across 75 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 76th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $866 44
2022 General $111 1
2021 General $194 9
2020 General $77 5
2019 General $239 16

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Hos Loftus
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Hos Loftus were reported at $866. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Hos Loftus Psychiatry median Middle half National median
2019 $239 $184 $59–$605 $163
2020 $77 $119 $36–$372 $114
2021 $194 $143 $43–$576 $132
2022 $111 $153 $50–$590 $149
2023 $0 $170 $56–$651 $160
2024 $0 $179 $57–$673 $164
2025 $866 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Teva Pharmaceuticals USA, Inc. $303 8 payments
  2. Novartis Pharmaceuticals Corporation $231 15 payments
  3. US WorldMeds, LLC $173 12 payments
  4. AbbVie, Inc. $168 7 payments
  5. Eisai Inc. $141 8 payments
  6. Argenx US, Inc. $70 3 payments
  7. Mitsubishi Tanabe Pharma America, Inc. $64 3 payments
  8. Lilly USA, LLC $63 4 payments
  9. SK Life Science, Inc. $45 2 payments
  10. Amgen Inc. $38 2 payments
  11. Other $192 11 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $1,233 71 payments
  2. Education $223 2 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $31 2 payments
Products named General payments · program years 2019–2025
  1. AIMOVIG $269 17 payments
  2. Leqembi $141 8 payments
  3. UBRELVY $140 6 payments
  4. QULIPTA $105 4 payments
  5. Austedo XR $80 6 payments
  6. VYVGART Hytrulo $70 3 payments
  7. Radicava $64 3 payments
  8. KISUNLA $63 4 payments
  9. Apokyn $62 4 payments
  10. Xadago $43 3 payments
  11. Other $222 13 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 29 drugs

Part D claims

1,184

Median for Neurology: 833

Drug cost

$166,557

Median for Neurology: $202,670

Branded share of claims

20.4%

Median for Neurology: 25.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gamunex-C Immune Globul G/Gly/Iga Avg 46 Brand 31 $97,343
Briviact Brivaracetam Brand 18 $41,570
Lacosamide Generic 59 $5,156
Levetiracetam Generic 148 $3,362
Primidone Generic 98 $2,221
Oxcarbazepine Generic 61 $2,093
Divalproex Sodium Er Divalproex Sodium Brand 11 $2,083
Carbidopa-Levodopa Carbidopa/Levodopa Brand 115 $1,995
Gabapentin Generic 99 $1,751
Carbatrol Carbamazepine Brand 11 $1,148

The 10 drugs with the highest cost, of 29 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 14 billing codes

Paid by Medicare

$21,205

Medicare's payments for the services billed

Medicare patients

153

Average age 73

Services billed

275

82 women, 71 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 50%
Depression 44%
Diabetes 39%
Chronic kidney disease 36%
Ischemic heart disease 32%
Heart failure 25%
Alzheimer's or dementia 25%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

75 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record